Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma - 12/08/11
Reprints: Peter G. Rose, MD, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology/A81, 9500 Euclid Ave, Cleveland, OH 44195Résumé |
Objective |
The objective of the study was to assess the effectiveness of primary chemoradiation for stage IB2 cervical carcinoma.
Study Design |
A retrospective study of patients treated with primary chemoradiation at selected hospitals in Cleveland, OH, from 1992 to 2006 was performed. Patients with regional or distant metastasis on pretreatment imaging were excluded. Patients received pelvic teletherapy with weekly concurrent cisplatin and high- or low-dose-rate brachytherapy.
Results |
Forty-nine patients with a median age of 51 years were identified. The majority of patients were white (81.6%) and had squamous cell carcinomas (81.6%) and a median tumor diameter of 5 cm (range, 4.1-10 cm). The median duration of follow-up was 41 months. Progression of disease was observed in 10 (20.4%) patients. The local control rate was 86%. At 36 months, the progression-free survival (PFS) was 79% and the overall survival (OS) was 86%.
Conclusion |
Primary chemoradiation has a high clinical response rate, PFS, and OS for women with stage IB2 cervical cancer.
Le texte complet de cet article est disponible en PDF.Key words : Cervical carcinoma, chemotherapy, radiotherapy, survival
Plan
| Cite this article as: Goksedef BPC, Kunos C, Belinson JL, et al. Concurrent cisplatin-based chemoradiation International Federation of Gynecology and Obstetrics stage IB2 cervical carcinoma. Am J Obstet Gynecol 2009;200:175.e1-175.e5. |
Vol 200 - N° 2
P. 175.e1-175.e5 - février 2009 Retour au numéro
Article précédent
- A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause
- David F. Archer, Larry Seidman, Ginger D. Constantine, James H. Pickar, Sophie Olivier
- Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis
- Yanfang Li, Wei Hu, De-Yu Shen, John J. Kavanagh, Siqing Fu
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?